Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.13 -0.05 (-0.33%)
Official Closing Price Updated: 7:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,140,944
Open 15.11
Bid (Size) 14.54 (3)
Ask (Size) 15.35 (3)
Prev. Close 15.18
Today's Range 15.01 - 15.15
52wk Range 12.57 - 15.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million. 
Via Benzinga
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
From Takeda Pharmaceutical Company Limited
Via Business Wire

Performance

YTD
+14.2%
+14.2%
1 Month
+8.8%
+8.8%
3 Month
+13.2%
+13.2%
6 Month
+1.9%
+1.9%
1 Year
+3.9%
+3.9%

More News

Read More
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire
Preview: Takeda Pharmaceutical's Earnings
Via Benzinga
Earnings Scheduled For January 30, 2025
Via Benzinga
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
From Takeda Pharmaceutical Company Limited
Via Business Wire
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Via Benzinga
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
Via Benzinga
Exposures Product Safety
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
Via Benzinga
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Via Benzinga
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
From Takeda Pharmaceutical Company Limited
Via Business Wire
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Via Benzinga
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
From Takeda Pharmaceutical Company Limited
Via Business Wire
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
From HUTCHMED (China) Limited
Via GlobeNewswire
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
Via Benzinga
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
Via Benzinga
Topics Climate Change
Exposures Climate
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
From Takeda Pharmaceutical Company Limited
Via Business Wire
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Via Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Via Benzinga
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire

Frequently Asked Questions

Is Takeda Pharmaceutical Company Limited American Depositary Shares (each publicly traded?
Yes, Takeda Pharmaceutical Company Limited American Depositary Shares (each is publicly traded.
What exchange does Takeda Pharmaceutical Company Limited American Depositary Shares (each trade on?
Takeda Pharmaceutical Company Limited American Depositary Shares (each trades on the New York Stock Exchange
What is the ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The ticker symbol for Takeda Pharmaceutical Company Limited American Depositary Shares (each is TAK on the New York Stock Exchange
What is the current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each?
The current price of Takeda Pharmaceutical Company Limited American Depositary Shares (each is 15.13
When was Takeda Pharmaceutical Company Limited American Depositary Shares (each last traded?
The last trade of Takeda Pharmaceutical Company Limited American Depositary Shares (each was at 03/19/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.